Inside IPEC–Americas: Excipient Audits and API Audits are Worlds Apart - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Inside IPEC–Americas: Excipient Audits and API Audits are Worlds Apart
The less complex nature of excipient manufacturers, as compared with API manufactures, carries many benefits.


Pharmaceutical Technology


Regulatory and cost benefits

In addition, GMP requirements for API manufacture are more explicit because of FDA requirements and guidelines from the International Conference on Harmonization. Official GMP requirements do not exist for excipients but standards are expressed in industry produced guidelines, whose application can vary greatly because of the range of processing involved. For example, the application of GMP standards for a salt producer that mines, purifies, and packages salt for use as an excipient would probably be very different from that of a synthetic excipient manufacturer.

There is one final significant difference between auditing excipient and API manufacturers. Because excipient manufacturers have numerous customers as compared with API manufacturers, it is feasible for excipient manufacturers to reduce audit assessment costs for their customers (and to themselves through a reduction in customer visits) by allowing the sharing of audit reports. It was for these reasons that IPEC–Americas formed its excipient GMP auditing subsidiary, International Pharmaceutical Excipients Auditing, Inc. (IPEA) in 2001 to assist excipient producers and their pharmaceutical customers. For example, the report of an IPEA third party audit requested by an excipient manufacturer can, if the company wishes, be shared with its potential customers. When this is publicized, it has served to reduce the number of new audit requests producers have received for up to two years after the IPEA audit.

Of note: An IPEC–China organization is being formed to join IPEC–Americas, IPEC–Europe and IPEC–Japan.Nevin Cheng of Shanghai Coating Technology, Ltd. will act as general manager for ongoing organizational efforts.

Irwin Silverstein, PhD, is vice-president of International Pharmaceutical Excipients Auditing Inc., the GMP auditing subsidiary of the International Pharmaceutical Excipients Council of the Americas. For more information, he can be contacted at


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
Source: Pharmaceutical Technology,
Click here